The Emirates Drug Establishment (EDE) has formally authorised Itvisma (onasemnogene abeparvovec), marking a new chapter for ...

Artificial intelligence is rapidly becoming medicine’s most powerful microscope, revealing patterns in human DNA that were ...

Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...

BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, in the drugmaker's second deal this year to expand its presence in rare diseases.

AMD Phase 3 timing, Otsuka funding to 2028, and mixed 4D-710 data with financial risk. See why FDMT stock is a hold.

Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...

A 10-month-old baby who sparked nationwide headlines after receiving a first-of-its kind gene-editing treatment was released ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

A family on Brookside’s “Candy Cane Lane” has transformed their home into a winter wonderland to raise money for their son's ...

In a person living with HIV, proviruses—strands of HIV DNA—are typically integrated into the T cell genome and become a ...

The baby saved from a rare disease by a first-ever personalized gene fix has reached a big milestone, taking his first steps ...

This year saw notable progress in head and neck cancers, Huntington's disease, personalized genetic therapy, and heart ...